• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Rapport Therapeutics Inc.

    4/24/25 6:08:54 AM ET
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RAPP alert in real time by email
    DEFA14A 1 d940377ddefa14a.htm DEFA14A DEFA14A
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    (Amendment No. )

     

     

    Filed by the Registrant ☒

    Filed by a Party other than the Registrant ☐

    Check the appropriate box:

     

    ☐

    Preliminary Proxy Statement

     

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ☐

    Definitive Proxy Statement

     

    ☒

    Definitive Additional Materials

     

    ☐

    Soliciting Material under §240.14a-12

    RAPPORT THERAPEUTICS, INC.

    (Name of Registrant as Specified in Its Charter)

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

     

    ☒

    No fee required

     

    ☐

    Fee paid previously with preliminary materials

     

    ☐

    Fee computed on table in exhibit required by Item 25(b) Exchange Act Rules 14a-6(i)(1) and 0-11

     

     
     


     

     

     

      LOGO

    RAPPORT THERAPEUTICS, INC.

    1325 BOYLSTON STREET, SUITE 401

    BOSTON, MA 02215

     

     

    V68858-P24981

     

     

     

    LOGO

     

    You invested in RAPPORT THERAPEUTICS, INC. and it’s time to vote!

    You have the right to vote on proposals being presented at the 2025 Annual Meeting, which is being held virtually. Important Notice Regarding the Availability of Proxy Materials for the 2025 Annual Meeting of Stockholders to be Held on June 17, 2025.

    Get informed before you vote

    View the Notice, Proxy Statement and 2024 Annual Report online OR you can receive a free paper or email copy of the material(s) by requesting prior to June 3, 2025. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.

     

      LOGO

     

    Smartphone users       LOGO   

    Vote Virtually at the Meeting*

     

    Point your camera here and

    vote without entering a

    control number

          June 17, 2025
          9:30 AM ET
         

      LOGO

           Virtually at:
           www.virtualshareholdermeeting.com/RAPP2025
            
              

     

     

    *Please check the meeting materials for any special requirements for meeting attendance.


    Vote at www.ProxyVote.com

     

     

    THIS IS NOT A VOTABLE BALLOT

    This is an overview of the proposals being presented at the

    upcoming 2025 Annual Meeting. Please follow the instructions

    on the reverse side to vote on these important matters.

     

     Voting Items

     

     

    Board

    Recommends

     

    1.

      To elect Reid Huber, Ph.D., John Maraganore, Ph.D., and Wendy B. Young, Ph.D. as Class I Directors.  
     
      Nominees:  
     
       

    01)  Reid Huber, Ph.D.

    02)  John Maraganore, Ph.D.

    03)  Wendy B. Young, Ph.D.

      LOGO  For
     

    2.

      To ratify the appointment of PricewaterhouseCoopers LLP as Rapport’s independent registered public accounting firm for the fiscal year ending December 31, 2025.  

    LOGO  For

    NOTE: In their discretion, the proxies are authorized to vote upon such other business as may properly come before the meeting or any continuations, adjournments and postponements thereof.

       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
        
       
       
       

     

    Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”.

    V68859-P24981

    Get the next $RAPP alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RAPP

    DatePrice TargetRatingAnalyst
    11/19/2025$47.00Buy
    BTIG Research
    9/16/2025$44.00Buy
    Truist
    8/6/2025$31.00Buy
    H.C. Wainwright
    4/8/2025Mkt Outperform
    Citizens JMP
    7/2/2024Buy
    TD Cowen
    7/2/2024$35.00Buy
    Jefferies
    7/2/2024$35.00Buy
    Stifel
    More analyst ratings

    $RAPP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BTIG Research initiated coverage on Rapport Therapeutics with a new price target

    BTIG Research initiated coverage of Rapport Therapeutics with a rating of Buy and set a new price target of $47.00

    11/19/25 8:58:22 AM ET
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Truist initiated coverage on Rapport Therapeutics with a new price target

    Truist initiated coverage of Rapport Therapeutics with a rating of Buy and set a new price target of $44.00

    9/16/25 8:09:40 AM ET
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Rapport Therapeutics with a new price target

    H.C. Wainwright initiated coverage of Rapport Therapeutics with a rating of Buy and set a new price target of $31.00

    8/6/25 8:02:07 AM ET
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RAPP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Operating Officer Gault Cheryl exercised 5,000 shares at a strike of $1.80 and sold $150,486 worth of shares (5,000 units at $30.10) (SEC Form 4)

    4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)

    12/1/25 4:17:37 PM ET
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Ceesay Abraham sold $275,047 worth of shares (10,916 units at $25.20), decreasing direct ownership by 1% to 573,746 units (SEC Form 4)

    4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)

    11/18/25 4:27:41 PM ET
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Scientific Officer Bredt David sold $214,091 worth of shares (8,500 units at $25.19), decreasing direct ownership by 2% to 401,142 units (SEC Form 4)

    4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)

    11/18/25 4:24:43 PM ET
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RAPP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Huber Reid M bought $499,374 worth of shares (20,400 units at $24.48) (SEC Form 4)

    4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)

    9/15/25 4:05:09 PM ET
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Paul Steven M bought $1,027,111 worth of shares (41,666 units at $24.65) (SEC Form 4)

    4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)

    9/15/25 4:05:04 PM ET
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Young Wendy B. bought $79,100 worth of shares (3,500 units at $22.60), increasing direct ownership by 58% to 9,500 units (SEC Form 4)

    4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)

    9/11/25 6:13:48 PM ET
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RAPP
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Rapport Therapeutics Inc.

    SCHEDULE 13G/A - Rapport Therapeutics, Inc. (0002012593) (Subject)

    11/14/25 1:09:26 PM ET
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Rapport Therapeutics Inc.

    10-Q - Rapport Therapeutics, Inc. (0002012593) (Filer)

    11/6/25 7:30:52 AM ET
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rapport Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Rapport Therapeutics, Inc. (0002012593) (Filer)

    11/6/25 7:15:27 AM ET
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RAPP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Rapport Therapeutics Announces New Data and Post Hoc Analysis Demonstrating the Magnitude and Consistency of RAP-219's Clinical Response in Patients with Focal Onset Seizures

    Post-hoc analysis of RAP-219 Phase 2a data showed early onset of action and consistency of median response over the entire treatment period, along with consistent efficacy data regardless of patients' disease severity  RAP-219 demonstrated meaningful improvements in patient-reported seizure severity among those with moderate or greater baseline impairment BOSTON and SAN DIEGO, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (NASDAQ:RAPP) (Rapport or the Company), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced new data and post hoc

    12/5/25 9:00:00 AM ET
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rapport Therapeutics to Present New Phase 2a Data Analysis Further Characterizing RAP-219 in Focal Onset Seizures at 2025 American Epilepsy Society Annual Meeting

    BOSTON and SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (NASDAQ:RAPP) ("Rapport" or the "Company"), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced that the Company will present the results of its Phase 2a trial of RAP-219 in focal onset seizures (FOS), along with new efficacy analysis, at the upcoming 2025 American Epilepsy Society (AES) Annual Meeting, taking place December 5–9, 2025, in Atlanta. The Company will present during the meeting's poster sessions and will also host a dedicated Scientific Exhibit Room high

    11/25/25 7:00:00 AM ET
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rapport Therapeutics to Participate in Upcoming Investor Conferences

    BOSTON and SAN DIEGO, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (NASDAQ:RAPP) ("Rapport" or the "Company"), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced that management plans to participate in the following upcoming investor events: Stifel 2025 Healthcare Conference (New York City, NY) – fireside chat on Thursday, November 13, 2025, at 1:20-1:50pm ET. Jefferies Global Healthcare Conference (London, UK) – fireside chat on Monday, November 17, 2025, at 1:00-1:25pm GMT/8:00-8:25am ET. Interested parties may access the live an

    11/5/25 4:05:00 PM ET
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RAPP
    Leadership Updates

    Live Leadership Updates

    View All

    Alto Neuroscience Appoints Biotech Industry Veteran, Raymond Sanchez, M.D., to Its Board of Directors

    Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the appointment of Raymond Sanchez, M.D., to its Board of Directors, effective August 12, 2025. Dr. Sanchez is a highly accomplished executive with a strong background in medicine and over 20 years of strategic experience in the life sciences industries. "We are delighted to welcome Ray to our Board of Directors as we continue advancing multiple clinical-stage precision psychiatry programs," said Amit Etkin, M.D., Ph.D., founder and chief executive officer of Alto Neuroscience. "Ray brings an impress

    8/13/25 8:03:00 AM ET
    $ANRO
    $CERE
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rapport Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

    Results of positron emission tomography (PET) trial and second multiple ascending dose (MAD-2) trial support RAP-219's transformative potential for epilepsy and other central nervous system (CNS) disorders Continued momentum in the Phase 2a trial of RAP-219 in patients with refractory focal epilepsy, with topline results expected in the third quarter of 2025Expect to initiate a Phase 2a trial in patients with bipolar mania in the third quarter of 2025, with topline results expected in the first half of 2027  Appointed recognized translational and clinical drug development leader, Jeffrey Sevigny, M.D., as chief medical officer  Ended the year with $305.3 million in cash, cash equivalents, an

    3/11/25 7:00:00 AM ET
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rapport Therapeutics Announces Appointment of Dr. Jeffrey Sevigny as Chief Medical Officer to Drive Clinical Strategy and Precision Medicine Development

    BOSTON and SAN DIEGO, March 03, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (NASDAQ:RAPP), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients suffering from central nervous system (CNS) disorders, today announced the appointment of Dr. Jeffrey Sevigny as chief medical officer (CMO), effective immediately. A physician-scientist with more than 15 years of leadership in translational and clinical drug development, Dr. Sevigny has spearheaded groundbreaking research across neuroscience and rare diseases. His experience spans the full spectrum of development, from discovery to late-stage clinical trials an

    3/3/25 7:00:00 AM ET
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RAPP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Rapport Therapeutics Inc.

    SC 13G - Rapport Therapeutics, Inc. (0002012593) (Subject)

    11/14/24 5:13:31 PM ET
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Rapport Therapeutics Inc.

    SC 13G/A - Rapport Therapeutics, Inc. (0002012593) (Subject)

    11/14/24 3:11:15 PM ET
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Rapport Therapeutics Inc.

    SC 13G - Rapport Therapeutics, Inc. (0002012593) (Subject)

    11/13/24 12:26:41 PM ET
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RAPP
    Financials

    Live finance-specific insights

    View All

    Rapport Announces Positive Topline Results from Phase 2a Clinical Trial of RAP-219 in Patients with Focal Onset Seizures

    Trial met primary long episode endpoints with high statistical significance, and RAP-219 was generally well toleratedPatients achieved 77.8% reduction in clinical seizures (p=0.01), with 24% achieving seizure freedom for the 8-week treatment period (p<0.0001)Data support advancement of RAP-219 into Phase 3 registrational trialsCompany to host a conference call today at 8:00 a.m. ET BOSTON and SAN DIEGO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (NASDAQ:RAPP) ("Rapport" or the "Company"), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today

    9/8/25 6:00:00 AM ET
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rapport Therapeutics to Announce Topline Results for RAP-219 Phase 2a Trial in Focal Onset Seizures on Monday, September 8, 2025

    BOSTON and SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (NASDAQ:RAPP) ("Rapport" or the "Company"), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced that it will host a conference call and live webcast at 8:00 am ET on September 8, 2025, to report topline results for the Phase 2a trial of RAP-219 in patients with drug-resistant focal onset seizures. Individuals interested in listening to the live conference call may do so through this webcast link or by dialing (800) 715-9871 in the U.S. or (646) 307-1963 for other

    9/5/25 4:05:00 PM ET
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care